These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 4356456)

  • 21. HPMPC, a broad-spectrum topical antiviral agent, inhibits herpes simplex virus type 1 replication and promotes healing of dendritic keratitis in the New Zealand rabbit ocular model.
    Gordon YJ; Romanowski EG; Araullo-Cruz T
    Cornea; 1994 Nov; 13(6):516-20. PubMed ID: 7842711
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nucleic acids. 3. Antiviral activity of nucleotides and dinucleoside phosphates containing ara-cytidine.
    Renis HE; Hollowell CA; Underwood GE
    J Med Chem; 1967 Sep; 10(5):777-82. PubMed ID: 4292736
    [No Abstract]   [Full Text] [Related]  

  • 23. In vitro and in vivo resistance of herpes simplex virus to 9-(2-hydroxyethoxymethyl)guanine (acycloguanosine).
    Smith KO; Kennell WL; Poirier RH; Lynd FT
    Antimicrob Agents Chemother; 1980 Feb; 17(2):144-50. PubMed ID: 6247967
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cutaneous herpes simplex virus infection of the guinea pig: lack of resistance to acyclovir and phosphonoformic acid after topical treatment.
    Poryo A; Wigand R
    Med Microbiol Immunol; 1984; 173(4):219-24. PubMed ID: 6096685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new topical treatment for resistant herpes simplex infections.
    Snoeck R; Andrei G; De Clercq E; Gerard M; Clumeck N; Tricot G; Sadzot-Delvaux C
    N Engl J Med; 1993 Sep; 329(13):968-9. PubMed ID: 8395657
    [No Abstract]   [Full Text] [Related]  

  • 26. Acyclic antimetabolite therapy of experimental herpes simplex keratitis.
    Pavan-Langston D; Campbell R; Lass J
    Am J Ophthalmol; 1978 Nov; 86(5):618-23. PubMed ID: 213976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Successful treatment of progressive mucocutaneous infection due to acyclovir- and foscarnet-resistant herpes simplex virus with (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC).
    Snoeck R; Andrei G; Gérard M; Silverman A; Hedderman A; Balzarini J; Sadzot-Delvaux C; Tricot G; Clumeck N; De Clercq E
    Clin Infect Dis; 1994 Apr; 18(4):570-8. PubMed ID: 8038312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NDA filed to treat refractory herpes.
    AIDS Patient Care STDS; 1997 Apr; 11(2):103. PubMed ID: 11361756
    [No Abstract]   [Full Text] [Related]  

  • 29. The spectrum of antiviral activities of acyclovir in vitro and in vivo.
    Collins P
    J Antimicrob Chemother; 1983 Sep; 12 Suppl B():19-27. PubMed ID: 6313598
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of 1-beta-D-ribofuranosyl1-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on herpes and vaccinia keratitis and encephalitis in laboratory animals.
    Sidwell RW; Allen LB; Khare GP; Huffman JH; Witkowski JT; Simon LN; Robins RK
    Antimicrob Agents Chemother; 1973 Feb; 3(2):242-6. PubMed ID: 4790589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A comparison of phosphonoacetic acid and phosphonoformic acid activity in genital herpes simplex virus type 1 and type 2 infections of mice.
    Kern ER; Richards JT; Overall JC; Glasgow LA
    Antiviral Res; 1981 Nov; 1(4):225-35. PubMed ID: 6280607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phosphonoacetic acid treatment of shope fibroma and vaccinia virus skin infections in rabbits.
    Friedman-Kien AE; Fondak AA; Klein RJ
    J Invest Dermatol; 1976 Feb; 66(02):99-102. PubMed ID: 1245751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral antiviral drugs in experimental herpes simplex keratitis.
    Kaufman HE; Varnell ED; Centifanto-Fitzgerald YM; De Clercq E; Kissling GE
    Antimicrob Agents Chemother; 1983 Dec; 24(6):888-91. PubMed ID: 6318664
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Therapeutic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, caffeic acid oxidation product, and trisodiumphosphonoformate on cutaneous herpes simplex virus type 1 infection in guinea pigs.
    Helbig B; Sauerbrei A; Klöcking R; Wutzler P; Wicht N; Wiedemann U; Herrmann G
    J Med Virol; 1987 Nov; 23(3):303-9. PubMed ID: 2828526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Inhibition of herpesvirus multiplication in guinea pig skin by antiviral compounds.
    Alenius S
    Arch Virol; 1980; 65(2):149-56. PubMed ID: 6252867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemotherapy of herpetic infections].
    Barinskiĭ IF; L'vov ND; Samoĭlovich EO
    Vopr Virusol; 1986; 31(1):6-18. PubMed ID: 3515765
    [No Abstract]   [Full Text] [Related]  

  • 37. Antiviral drugs.
    Kaufman HE
    Int J Dermatol; 1977; 16(6):464-75. PubMed ID: 408279
    [No Abstract]   [Full Text] [Related]  

  • 38. [Effect of riodoxol on herpes simplex virus morphogenesis in experimental eye infection].
    Stebaeva LF; Nikolaeva IS; Pershin GN
    Vopr Virusol; 1982; (1):90-4. PubMed ID: 6280397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpes simplex virus hepatitis in mice: effects of treatment with trisodium phosphonoformate.
    Ulbricht A; Färber I; Wutzler P
    Acta Virol; 1985 Dec; 29(6):493-8. PubMed ID: 2869661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Progressive mucocutaneous herpes simplex infection due to acyclovir-resistant virus in an immunocompromised patient: correlation of viral susceptibilities and plasma levels with response to therapy.
    Bean B; Fletcher C; Englund J; Lehrman SN; Ellis MN
    Diagn Microbiol Infect Dis; 1987 Jul; 7(3):199-204. PubMed ID: 2820649
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.